4.7 Review

Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development

Journal

CELL HOST & MICROBE
Volume 13, Issue 3, Pages 250-262

Publisher

CELL PRESS
DOI: 10.1016/j.chom.2013.02.009

Keywords

-

Funding

  1. National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI-067665, AI-033774, AI-052733, AI-033142]
  2. National Heart, Lung, and Blood Institute (NHLBI) [HL-059842]
  3. Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine [AI-51519]
  4. Aeras TB Vaccine Foundation
  5. Food and Drug Administration (FDA) [1U18 FD004012/01]
  6. Bill and Melinda Gates Grand Challenge award
  7. TB Vaccine Accelerator Program award

Ask authors/readers for more resources

There is an urgent need for new and better vaccines against tuberculosis (TB). Current vaccine design strategies are generally focused on the enhancement of cell-mediated immunity. Antibody-based approaches are not being considered, mostly due to the paradigm that humoral immunity plays little role in the protection against intracellular pathogens. Here, we reappraise and update the increasing evidence for antibody-mediated immunity against Mycobacterium tuberculosis, discuss the complexity of antibody responses to mycobacteria, and address mechanism of protection. Based on these findings and discussions, we challenge the common belief that immunity against M. tuberculosis relies solely on cellular defense mechanisms, and posit that induction of antibody-mediated immunity should be included in TB vaccine development strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available